Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib versus best available therapy in thrombocytopenic myelofibrosis
NL-OMON40900Phase 3Active, not recruiting
- Sponsor
- CTI BioPharma Corp.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pacritinib in myelofibrosis (MF) (3 arms), sponsored by CTI BioPharma Corp. Primary endpoints: Spleen volume response rate and Total symptom score response rate. Started Oct 2014; status: active, not recruiting.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON40900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40900.